Chronic Heart Failure Therapeutics Market Size in the 7MM was ~ USD 8,000 Million in 2023, is expected to grow by 2034 | DelveInsight

DelveInsight's "Congestive Heart Failure Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of CHF, historical, and forecasted epidemiology as well as the CHF market trends in the US, EU4 (Germany, France, Italy, Spain), and the UK, and Japan.

Discover Key Insights into the Chronic Heart Failure Market with DelveInsight's In-Depth Report @ Chronic Heart Failure Market Size [https://www.delveinsight.com/sample-request/chronic-heart-failure-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Chronic Heart Failure Market Report

* In December 2024:- AstraZeneca- A Phase IIb Two-Cohort, Randomised, Placebo-controlled, Double-blind, Multi-centre, Dose-ranging Study of AZD5462 in Stable Patients With Chronic Heart Failure. The main purpose of this study is to evaluate the effect of AZD5462 on cardiac function in participants with chronic heart failure (HF). This is a Phase IIb randomized, double-blind, placebo-controlled, multi-center, dose-ranging study to evaluate the efficacy, safety, and pharmacokinetic (PK) of AZD5462 on top of standard of care in 2 cohorts of participants with HF: Cohort A, and Cohort B.
* In December 2024:- Regeneron Pharmaceuticals- A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of a Single Dose of REGN5381, an NPR1 Monoclonal Antibody Agonist, in Patients With Chronic Heart Failure With Reduced Ejection Fraction. This study is researching an experimental drug called REGN5381 (called "study drug"). The study is focused on patients with heart failure with reduced ejection fraction (ie, the heart is not functioning as well as it should).
* Driven by multiple factors, the number and distribution of reported cases of CHF have increased over time in the 7MM, among which the US contributed the major patient share.
* As per DelveInsight's estimate, the total diagnosed prevalent cases of CHF in the 7MM were approximately 20,360,000 in 2023.
* In 2023, the percentage of diagnosed prevalence of males with heart failure in the US was 55%, and that for females was 45%.
* In the UK, among all the four NYHA Classes of heart failure, Class II accounted for around 45% of the total diagnosed prevalent heart failure cases in 2023.
* Among the EU4, the highest number of diagnosed prevalent cases of CHF were found in Germany, followed by France, and Spain, and the lowest number of diagnosed prevalent cases in Italy in 2023.
* In Japan, the age-specific dignosed prevalent cases of heart failure in 2023 accounted for approximately 4,444,000 (for age group more than 60 years), 634,900 (for age group 40-59 years), and 211,600 (for age group below 39 years).
* The leading Chronic Heart Failure Companies such as Novartis, Boehringer Ingelheim, Eli Lilly and Company, Bayer, Cytokinetics, BioCardia, Novo Nordisk, Mesoblast, and others.
* Promising Chronic Heart Failure Therapies such as Ertugliflozin, Metolazone, AZD5462, Vericiguat (Verquvo, BAY1021189), mRNA-0184, rhNRG-1 , and others.

Stay ahead in the Chronic Heart Failure Therapeutics Market with DelveInsight's Strategic Report @ Chronic Heart Failure Market Outlook [https://www.delveinsight.com/sample-request/chronic-heart-failure-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Chronic Heart Failure Epidemiology Segmentation in the 7MM

* Total Chronic Heart Failure Diagnosed Prevalent Cases
* Chronic Heart Failure Gender-Specific Cases
* Chronic Heart Failure Ejection fraction-specific cases
* Chronic Heart Failure NYHA class-specific cases
* Chronic Heart Failure Type-specific cases
* Chronic Heart Failure Age-specific cases

Download the report to understand which factors are driving Chronic Heart Failure epidemiology trends @ Chronic Heart Failure Prevalence [https://www.delveinsight.com/sample-request/chronic-heart-failure-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Marketed Congestive Heart Failure Drugs

* INJECTAFER (ferric carboxymaltose injection)/FERINJECT: American Regent, Vifor, and Daiichi Sankyo

INJECTAFER (ferric carboxymaltose injection) is indicated for the treatment of iron deficiency in adult patients with heart failure; Iron Deficiency Anemia (IDA) in adult and pediatric patients 1-year of age and older who have either intolerance to oral iron or unsatisfactory response to oral iron; and adult patients with IDA who have non-dialysis dependent chronic kidney disease. Its dosing for iron deficiency in adult patients with heart failure and NYHA class II/III is based on patient weight and hemoglobin level starting at a single 500mg dose up to two 1000mg doses separated by six weeks.

* INPEFA (sotagliflozin): Lexicon Pharmaceuticals and Viatris

INPEFA (sotagliflozin) is an oral inhibitor of two proteins responsible for glucose regulation known as SGLT2 and SGLT1. SGLT2 is responsible for glucose reabsorption by the kidney, and SGLT1 is responsible for glucose absorption in the gastrointestinal tract. In May 2023, Lexicon Pharmaceuticals announced that the US FDA had approved INPEFA (sotagliflozin) to reduce the risk of cardiovascular death, hHF, and uHF visits in adults with heart failure or type 2 diabetes mellitus, chronic kidney disease, and other cardiovascular risk factors. The broad label encompasses heart failure patients across the full range of LVEF, including HFpEF and HFrEF, and for patients with or without diabetes. The approval of INPEFA in heart failure indication, along with the breadth of the label, is a major milestone in Lexicon's path to fulfilling its mission of pioneering medicines that transform patients' lives.

Chronic Heart Failure Emerging Drugs

* Omecamtiv mecarbil: Cytokinetics

Omecamtiv mecarbil is a selective small-molecule cardiac myosin activator. It is designed to directly target the contractile mechanism or pumping function of the heart. By stimulating cardiac myosin, a protein responsible for converting chemical energy into the mechanical force that helps the heart contract, omecamtiv mecarbil may improve cardiac muscle performance. Preclinical research has shown that cardiac myosin activators increase cardiac contractility without affecting intracellular myocyte calcium concentrations or myocardial oxygen consumption. It has completed its Phase III for CHF and its Phase III for HFrEF is anticipated in the fourth quarter of 2024.

* KERENDIA (finerenone): Bayer

Finerenone is a nonsteroidal, selective Mineralocorticoid Receptor (MR) antagonist that has been shown to block the harmful effects of MR overactivation. MR overactivation contributes to Chronic Kidney Disease (CKD) progression and cardiovascular damage, which can be driven by metabolic, hemodynamic, or inflammatory and fibrotic factors. Finerenone is marketed as KERENDIA or, in some countries, as FIRIALTA, and approved for the treatment of adult patients associated with Type II Diabetes (T2D) in more than 90 countries worldwide, including in China, Europe, Japan, and the US. It has completed its Phase III trial for heart and left ventricular ejection fraction =40% and the company is anticipating the first submission of the drug by mid-2025.

Get In-Depth Knowledge on Chronic Heart Failure Market Trends and Forecasts with DelveInsight @ Chronic Heart Failure Treatment Market [https://www.delveinsight.com/sample-request/chronic-heart-failure-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Chronic Heart Failure Companies

Novartis, Boehringer Ingelheim, Eli Lilly and Company, Bayer, Cytokinetics, BioCardia, Novo Nordisk, Mesoblast, and others

Chronic Heart Failure Market Outlook

After a scarcity of sustainable new therapies for more than a decade, new classes of agents for the treatment of patients with CHF were approved by the US FDA - VERQUVO (vericiguat), ENTRESTO (sacubitril/valsartan), a combined Angiotensin Receptor-neprilysin Inhibitor (ARNI) and CORLANOR (ivabradine), a sinoatrial node modulator. Both drugs are recommended for use as part of a comprehensive medical therapy regimen. Recently approved INJECTAFER (ferric carboxymaltose injection)/FERINJECT by American Regent, Vifor, and Daiichi Sankyo and INPEFA (sotagliflozin) by Lexicon Pharmaceuticals and Viatris, in 2023 are the newest additions for treating heart failure. These drugs are indicated for the treatment of iron deficiency in adult patients with heart failure and to reduce the risk of cardiovascular death, hHF, and uHF visits in adults with heart failure or type 2 diabetes mellitus, chronic kidney disease, and other cardiovascular risk factors, respectively. VERQUVO is a stimulator of soluble guanylate cyclase.

Chronic Heart Failure Drugs Market

Currently, heart failure treatment depends on angiotensin-converting enzyme inhibitors, angiotensin receptor II blockers, beta-blockers, and diuretics. Other therapies, such as aldosterone antagonists, amiodarone, antiaggregants, anticoagulants, calcium antagonists, diuretics, and nitrates, are used to treat patients affected by heart failure. The majority of therapies are prescribed in combination, and beta-blockers are one of the most prescribed classes. Among the approved therapies, ENTRESTO is Novartis' one of the most important drugs, and its revenue is expected to rise in the next years. At present, ENTRESTO leads the CHF market among the approved therapies.

Unlock Strategic Insights with DelveInsight's Comprehensive Chronic Heart Failure Market Report @ Chronic Heart Failure Market Drivers and Barriers [https://www.delveinsight.com/sample-request/chronic-heart-failure-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Chronic Heart Failure Market Report

* Coverage- 7MM
* Study Period- 2020-2034
* Chronic Heart Failure Companies- Novartis, Boehringer Ingelheim, Eli Lilly and Company, Bayer, Cytokinetics, BioCardia, Novo Nordisk, Mesoblast, and others.
* Chronic Heart Failure Therapies- Ertugliflozin, Metolazone, AZD5462, Vericiguat (Verquvo, BAY1021189), mRNA-0184, rhNRG-1, and others.
* Chronic Heart Failure Market Dynamics: Chronic Heart Failure Market Drivers and Barriers
* Chronic Heart Failure Unmet Needs, KOL's views, Analyst's views, Chronic Heart Failure Market Access and Reimbursement

Table of Content

1. Key Insights

2. Chronic Heart Failure Report Introduction

3. Chronic Heart Failure Executive Summary

4. Chronic Heart Failure Market Overview at a Glance

5. Chronic Heart Failure Key Events

6. Chronic Heart Failure Epidemiology and Market Forecast Methodology

7. Chronic Heart Failure Disease Background and Overview

9. Chronic Heart Failure Epidemiology and Patient Population

10. Patient Journey

11. Chronic Heart Failure Marketed Drugs

12. Chronic Heart Failure Emerging Drugs

13. Chronic Heart Failure: 7MM Analysis

14. Chronic Heart Failure Unmet needs

15. Chronic Heart Failure SWOT Analysis

16. Chronic Heart Failure KOL Views

17. Chronic Heart Failure Market Access and Reimbursement

18. Appendix

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=chronic-heart-failure-therapeutics-market-size-in-the-7mm-was-usd-8000-million-in-2023-is-expected-to-grow-by-2034-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/case-study/respiratory-domain-conference-coverage



This release was published on openPR.